Streetbeat News

Regulatory

ENPH

Enphase Energy has introduced a solution for expanding legacy net energy metering (NEM) solar systems in California without transitioning to the less favorable NEM 3.0 tariff. This involves new system configurations with IQ Microinverters, IQ Batteries, and Enphase Power Control, approved by major utilities.

Portfolio Pulse from Benzinga Newsdesk

September 04, 2024 | 12:07 pm

ABBV

AbbVie's VRAYLAR, an atypical antipsychotic medication, has received a reimbursement recommendation from Canada's drug agency for treating schizophrenia in adults. This follows successful negotiations and a letter of intent, leading to its listing in Québec and federal plans.

Portfolio Pulse from Benzinga Newsdesk

September 04, 2024 | 12:02 pm

MCO

SPGI

The SEC has fined six major rating agencies, including Moody's, S&P Global, and Fitch, a total of $49 million for record-keeping failures. Moody's and S&P Global each face a $20 million penalty, while Fitch will pay $8 million. The agencies are enhancing compliance policies to address these issues.

Portfolio Pulse from Benzinga Neuro

September 04, 2024 | 11:45 am

CYN

Cyngn has been granted a new U.S. patent (No. 12,032,099) for a method to maintain the accuracy of data collected by autonomous vehicle sensors. This development could enhance the performance and reliability of Cyngn's autonomous vehicle technology.

Portfolio Pulse from Benzinga Newsdesk

September 04, 2024 | 11:17 am

AXSM

Axsome Therapeutics announced that the FDA has acknowledged the resubmission of its New Drug Application for AXS-07, a treatment for acute migraine. The FDA has classified it as a Class 2 resubmission with a PDUFA action goal date set for January 31, 2025.

Portfolio Pulse from Benzinga Newsdesk

September 04, 2024 | 11:04 am

MRK

Merck and EyeBio have launched a Phase 2b/3 trial for Restoret™ (MK-3000) to treat diabetic macular edema. This trial follows promising results from earlier studies, marking a significant step in developing new treatments for retinal diseases.

Portfolio Pulse from Benzinga Newsdesk

September 04, 2024 | 10:45 am

RIVN

TSLA

Former Tesla executive Rohan Patel predicts a decade of upheaval in the auto industry, emphasizing the need for efficiency and innovation over protectionist measures. Tesla CEO Elon Musk questions Rivian's financial reliance on Volkswagen amidst the latter's potential factory closures in Germany due to competitive pressures.

Portfolio Pulse from Anan Ashraf

September 04, 2024 | 10:41 am

IMUX

Immunic has enrolled the first patient in a Phase 2 trial of Vidofludimus Calcium (IMU-838) for treating post-COVID syndrome. This trial is investigator-sponsored and marks a significant step in exploring treatments for long-term COVID-19 effects.

Portfolio Pulse from Benzinga Newsdesk

September 04, 2024 | 10:32 am

MYGN

Myriad Genetics has decided to discontinue the second part of a study due to significant disparities between the GeneSight group and the control group, which was deemed not viable.

Portfolio Pulse from Benzinga Newsdesk

September 04, 2024 | 10:20 am

GM

The National Highway Traffic Safety Administration (NHTSA) has concluded its engineering analysis into 1,339,355 General Motors vehicles regarding a potential failure of the outboard front seat belt anchor cable. This closure indicates that no further action will be taken by the NHTSA on this matter.

Portfolio Pulse from Benzinga Newsdesk

September 04, 2024 | 9:44 am